Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001193125-23-092350
Filing Date
2023-04-05
Accepted
2023-04-05 16:35:33
Documents
9

Document Format Files

Seq Description Document Type Size
1 S-3 d407595ds3.htm S-3 201396
2 EX-4.4 d407595dex44.htm EX-4.4 195378
3 EX-4.5 d407595dex45.htm EX-4.5 83839
4 EX-5.1 d407595dex51.htm EX-5.1 9684
5 EX-23.2 d407595dex232.htm EX-23.2 2192
6 EX-FILING FEES d407595dexfilingfees.htm EX-FILING FEES 15971
7 GRAPHIC g407595cooley.jpg GRAPHIC 9896
8 GRAPHIC g407595g03t43.jpg GRAPHIC 64433
9 GRAPHIC g407595g07f40.jpg GRAPHIC 93571
  Complete submission text file 0001193125-23-092350.txt   732272
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-271144 | Film No.: 23803078
SIC: 2836 Biological Products, (No Diagnostic Substances)